The stock of Aptevo Therapeutics Inc (NASDAQ:APVO) is a huge mover today! About 157,054 shares traded hands. Aptevo Therapeutics Inc (NASDAQ:APVO) has risen 6.00% since September 5, 2016 and is uptrending. It has underperformed by 2.26% the S&P500.
The move comes after 8 months positive chart setup for the $59.94 million company. It was reported on Oct, 5 by Barchart.com. We have $5.15 PT which if reached, will make NASDAQ:APVO worth $47.95 million more.
According to Zacks Investment Research, “Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company’s platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.”
More notable recent Aptevo Therapeutics Inc (NASDAQ:APVO) news were published by: Seekingalpha.com which released: “Aptevo: An Orphaned Spinoff” on October 05, 2016, also Quotes.Wsj.com with their article: “News Aptevo Therapeutics Inc.APVO” published on July 24, 2016, Businesswire.com published: “Aptevo Therapeutics Completes Separation from Emergent BioSolutions” on August 01, 2016. More interesting news about Aptevo Therapeutics Inc (NASDAQ:APVO) were released by: Seekingalpha.com and their article: “Aptevo Therapeutics: A Biotech Spinoff With Potential” published on September 22, 2016 as well as Globenewswire.com‘s news article titled: “Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 …” with publication date: July 15, 2016.
APVO Company Profile
Aptevo Therapeutics Inc. is a biotechnology company. The Firm focuses on oncology (cancer) and hematology (blood disease) therapeutics to manage patientsâ€™ lives. The Companyâ€™s segment is engaged in the discovery, development, commercialization and sale of sale oncology and hematology therapeutics. The Companyâ€™s core technology is the ADAPTIR (modular protein technology) platform. The Firm has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Companyâ€™s investigational-stage product candidates MOR209/ES414, ES210, ES425 and otlertuzumab are built on its ADAPTIR (modular protein technology) platform. The technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The mechanisms of action for MOR209/ES414, ES210, ES425 and otlertuzumab include redirected T-cell cytotoxicity (RTCC), by which a therapeutic molecule brings T-cells into contact with tumor cells and trigger tumor killing, or targeted delivery of cytokines (or immune modulating protein) to diseased cells. The structural differences of ADAPTIR molecules over monoclonal antibodies allow for the development of new ADAPTIR immunotherapeutics that engage disease targets in a manner and produce a signaling response. It provides product candidate generation, validation and pre-clinical and clinical development using the ADAPTIR platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.